Drugs / Renal Autologous Cell Therapy
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04115345 | Aug 2019 → Jan 2023 | chronic kidney disease, congenital anomaly of kidney and urinary tract | Prokidney | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-06-10 | Prokidney | Results ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates prokidney.com ↗ |
| 2023-11-13 | Prokidney | Results ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD and Provides Corporate Updates prokidney.com ↗
Updated positive interim Phase 2 data demonstrate potential efficacy of REACT® to preserve kidney function in moderate and high-risk diabetic CKD patients |
All press releases naming this drug 2 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Renal Autologous Cell Therapy | “We present our protocol and preliminary analysis of an IRB-approved, phase I single-group, open-label trial that tests the safety and efficacy of Renal Autologous Cell Therapy...” PMID 33647913 ↗ Mar 2021 |
| Known as | REACT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04115345 ↗ |
| Route | Other | “image-guided locoregional reinjection into the patient's renal cortex” PMID 33647913 ↗ Mar 2021 |